Business Description
ViroGates AS
ISIN : DK0061030574
Total Employee Number:
7Compare
Compare
Traded in other countries / regions
VIRO.DenmarkEP2.Germany IPO Date
2024-10-21Description
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.28 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.4 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.22 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37.1 | |||||
3-Year EBITDA Growth Rate | 25.2 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 50.3 | |||||
3-Year Book Growth Rate | -17.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.46 | |||||
9-Day RSI | 71.62 | |||||
14-Day RSI | 60.91 | |||||
3-1 Month Momentum % | -4.05 | |||||
6-1 Month Momentum % | -11.53 | |||||
12-1 Month Momentum % | 33.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.82 | |||||
Quick Ratio | 3.59 | |||||
Cash Ratio | 3.2 | |||||
Days Inventory | 363.98 | |||||
Days Sales Outstanding | 46.55 | |||||
Days Payable | 183.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.8 | |||||
Shareholder Yield % | 0.64 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.46 | |||||
Operating Margin % | -117.6 | |||||
Net Margin % | -113.54 | |||||
EBITDA Margin % | -117.1 | |||||
FCF Margin % | -76.43 | |||||
OCF Margin % | -76.43 | |||||
ROE % | -98.68 | |||||
ROA % | -48.42 | |||||
ROIC % | -148.72 | |||||
3-Year ROIIC % | -24.02 | |||||
ROC (Joel Greenblatt) % | -435.02 | |||||
ROCE % | -75.33 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.77 | |||||
PB Ratio | 5.86 | |||||
Price-to-Tangible-Book | 6.04 | |||||
EV-to-EBIT | -7.87 | |||||
EV-to-EBITDA | -7.87 | |||||
EV-to-Revenue | 9.21 | |||||
EV-to-FCF | -11.68 | |||||
Price-to-GF-Value | 1.61 | |||||
| Price-to-Net-Current-Asset-Value | 6.04 | |||||
| Price-to-Net-Cash | 8.06 | |||||
Earnings Yield (Greenblatt) % | -12.71 | |||||
FCF Yield % | -6.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ViroGates AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.205 | ||
| EPS (TTM) (€) | -0.162 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 80.09 | ||
| 14-Day RSI | 60.91 | ||
| 14-Day ATR (€) | 0.025321 | ||
| 20-Day SMA (€) | 1.3985 | ||
| 12-1 Month Momentum % | 33.96 | ||
| 52-Week Range (€) | 1.01 - 2.32 | ||
| Shares Outstanding (Mil) | 9.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ViroGates AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ViroGates AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 51 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 51 days | ||
| First quarter earnings conference call for 2026 | 2026-05-07 | 1.37 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.37 (+0.00%) | ||
| General meeting for 2026 | 2026-04-23 17:00 | 1.46 (-3.31%) | ||
| Annual report for 2025 | 2026-03-26 | 1.48 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 1.74 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 1.30 (-0.77%) |
Show
Entries
ViroGates AS Frequently Asked Questions
What is ViroGates AS(FRA:EP2)'s stock price today?
The current price of FRA:EP2 is €1.45. The 52 week high of FRA:EP2 is €2.32 and 52 week low is €1.01.
When is next earnings date of ViroGates AS(FRA:EP2)?
The next earnings date of ViroGates AS(FRA:EP2) is 2026-08-20.
Does ViroGates AS(FRA:EP2) pay dividends? If so, how much?
ViroGates AS(FRA:EP2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ViroGates AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers